- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: GDC0077 | inavolisib (proposed INN) | RG6114 | Ro7113755
Compound class: Synthetic organic
Comment: GDC-0077 is a potent and selective, orally available PI3K-p110α (PIK3CA) inhibitor, with potential antineoplastic activity. It is example 101 in patent US20170015678 (where it is named (S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepin-9- yl)amino)propanamide) . GDC-0077 is one of the agents in Genentech's oncology discovery pipeline.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Braun M-G, Hanan E, Staben ST, Heald RA, Macleod C, Elliott R. (2017)
Benzoxazepin oxazolidinone compounds and methods of use.
Patent number: US20170015678. Assignee: Genentech, Inc.. Priority date: 02/07/2015. Publication date: 19/01/2017.